Allogeneic hematopoietic stem cell transplantation (HSCT) using myeloablative-conditioning results in a reduced risk of relapse compared to reduced intensity regimens [1] [2] [3] . Fludarabine and intravenous (i.v.) busulfan (FluBu4) has been adopted as a myeloablative but limited toxicity conditioning regimen [4] [5] [6] . It has previously been shown that combined in vitro treatment with fludarabine and busulfan leads to synergistic cytotoxicity with maximal synergy being achieved when fludarabine is administered immediately prior to busulfan [5] [6] [7] [8] [9] [10] . However, FluBu4 may be administered both as either a concurrent 5-day regimen or a 9-day sequential, non-overlapping schedule [4] [5] [6] . Clinical data suggest that sequential regimens have increased antileukemia activity as well as decreased toxicity which allows for application in elderly, co-morbid patients [11, 12] . Because the clinical impact of sequence and schedule of administration of FluBu4 conditioning on toxicity and transplant outcomes is unknown, we sought to compare toxicity, survival and relapse outcomes between patients receiving HSCT with a concurrent 5-day versus a sequential 9-day FluBu4 regimen.
Allogeneic hematopoietic stem cell transplantation (HSCT) using myeloablative-conditioning results in a reduced risk of relapse compared to reduced intensity regimens [1] [2] [3] . Fludarabine and intravenous (i.v.) busulfan (FluBu4) has been adopted as a myeloablative but limited toxicity conditioning regimen [4] [5] [6] . It has previously been shown that combined in vitro treatment with fludarabine and busulfan leads to synergistic cytotoxicity with maximal synergy being achieved when fludarabine is administered immediately prior to busulfan [5] [6] [7] [8] [9] [10] . However, FluBu4 may be administered both as either a concurrent 5-day regimen or a 9-day sequential, non-overlapping schedule [4] [5] [6] . Clinical data suggest that sequential regimens have increased antileukemia activity as well as decreased toxicity which allows for application in elderly, co-morbid patients [11, 12] . Because the clinical impact of sequence and schedule of administration of FluBu4 conditioning on toxicity and transplant outcomes is unknown, we sought to compare toxicity, survival and relapse outcomes between patients receiving HSCT with a concurrent 5-day versus a sequential 9-day FluBu4 regimen.
At our institution, we initially administered FluBu4 in a sequential fashion over 9 days and subsequently shortened it to 5 days based on studies predominantly administering in a concurrent fashion [13] . We retrospectively analyzed consecutive adult patients who underwent FluBu4 and HSCT between January 2003 and December 2016.
Approval of the University of Illinois at Chicago Institutional Review Board was obtained before study commencement. One-hundred and two patients who received FluBu4 prior to HSCT were included in the final analysis. Supportive care measures and graft versus host disease (GVHD) prophylaxis were as previously published. Briefly, GVHD prophylaxis consisted of standard tacrolimus and methotrexate. Patients undergoing HSCT from an unrelated donor additionally received rabbit anti-thymocyte globulin 4.5 mg/kg. For all patients, anti-microbial prophylaxis consisted of levofloxacin during neutropenia, fluconazole until Day + 90 and acyclovir until Day + 180. In addition, patients received Pneumocystis jiroveci prophylaxis with either sulfamethoxazole-trimethoprim or monthly pentamidine until day + 180. Acute and chronic GVHD were graded using standard criteria [14, 15] . Mucositis was graded according to the NCI-CTCAE version 4.0 criteria. In patients experiencing mucositis, specific attention was paid to methotrexate dose reductions and omissions. Categorical data were analyzed by chi-square test and Fisher's exact test with cells < 5. Comparison of means and medians for continuous data were analyzed by the student's t-test and Wilcoxon rank-sum test respectively. Equality of survivor functions for GVHD-free, relapse-free survival (GRFS), overall survival (OS), progression free survival (PFS), and cumulative incidence of aGVHD and relapse were assessed using the Kaplan-Meier method and log-rank test. In timedependent Cox proportional hazards model, we estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association between a 9-day regimen and overall and progression-free survival. We assessed proportional hazards by testing for interaction between regimen and person time at risk for each of the outcomes and found no evidence suggesting violation of the proportionality assumption. Analyses were performed using GraphPad Prism (GraphPad, La Jolla, CA, USA) or SAS (SAS Institute, Cary, NC, USA).
Thirty-seven (36%) patients received the 5-day regimen, which consisted of fludarabine 40 mg/m 2 and intravenous Fig. 1 Higher cumulative incidence of Grade 2-4 (n = 10, 27% versus n = 24, 38%, p = 0.01) and Grade 3-4 (n = 4, 11% versus n = 21, 34%, p = 0.006) acute GVHD (aGVHD) in the 9-day group compared to the 5-day group busulfan (target AUC 4800 mmol-min per dose) administered daily from day 5 to day 2. In 65 (64%) patients, the 9-day regimen was administered, utilizing equivalent doses of fludarabine on day 9-day 6 and busulfan on day 5-day 2. Baseline characteristics including gender, race, median time to transplant, median lines of prior treatment, disease risk index, hematopoietic cell transplantation-comorbidity index (HCT-CI), donor type, and stem cell source were similar between the two groups ( Table 1) . Patients in the 9-day group were younger compared to the 5-day group (median age 45 versus 51 years, p = 0.003). Most patients were diagnosed with acute myeloid leukemia (n = 25, 68% versus n = 27, 42%), myelodysplastic syndrome (n = 3, 8% versus n = 7, 11%), or acute lymphoblastic leukemia (n = 6, 16% versus n = 13, 20%) in the 5-and 9-day group, respectively. Patients in the 5-day group received a higher mean CD34 + cell dose (7.17 ± 3.25 versus 4.24 ± 1.84, p = 0.03).
The median follow-up for patients in the 5 day group was 416 days (range: 44-1073) and 821 days (range: 12-4541) in the 9-day group. The median time to neutrophil (16 versus 18 days, p = 0.58) and platelet (12 versus 19 days, p = 0.7) engraftment was not different between the two groups. More patients receiving the 9-day regimen experienced NCI-CTCAE Grade 4 mucositis (53 (81.5%) versus 6 (16.2%) patients, p < 0.0001). Thus, 23 (35.4%) patients in the 9-day group versus 5 (13.5%) patients in the 5-day group required a day + 11 methotrexate dose reduction or omission (p = 0.02). This resulted in a higher cumulative incidence of both Grade 2-4 (n = 10, 27% versus n = 24, 38%, p = 0.01) and Grade 3-4 (n = 4, 11% versus n = 21, 34%, p = 0.006) acute GVHD (aGVHD) in the 9-day group compared to the 5-day group (Fig. 1) . In a multivariate analysis, patients receiving the 9-day regimen experienced greater risk of grade 3-4 aGVHD (HR = 6.84, 95% CI 1.28-36.60, p = 0.025). Additionally, extensive chronic GVHD (cGVHD) was found to be higher in the 9-day FluBu4 cohort (n = 7, 19% versus n = 26, 40% p = 0.047). We observed no differences in OS, PFS, or relapse rates between the 5 and 9-day regimen (Fig. 2) . Median one-year GRFS defined as the absence of grade 3-4 aGVHD, systemic therapy-requiring cGVHD, relapse, or death in the first post-HCT year was significantly worse for patients receiving a 9-day FluBu4 regimen (68.4 versus 144 days, p = 0.032; Fig. 2B) . In a multivariate analysis adjusted for HCT-CI, a trend toward longer GRFS with the 5-day regimen compared to the 9-day regimen was observed (HR = 1.66, 95% CI 0.96, 2.88, p = 0.07), although confidence intervals included 1.0.
We here demonstrate similar survival and relapse rates between a 5 and 9-day FluBu4 regimen, suggesting that concurrent administration of fludarabine and busulfan may not be necessary for synergistic cytotoxicity. At the same time, we observed increased mucositis, less MTX administration, and consequently higher aGVHD rates in patients receiving sequential 9-day FluBu4. The combination of intravenous busulfan and fludarabine, was first introduced as a myeloablative, reduced-toxicity conditioning regimen due to in vitro synergistic cytotoxicity and apparent reduction in extra-hematologic toxicity and transplantrelated mortality [4] [5] [6] [7] [8] [9] [10] . In early studies of FluBu4, fludarabine and busulfan were administered in a sequential, non-overlapping fashion, with the fludarabine preceding busulfan [4] . However, this regimen utilized oral busulfan, which is known to exhibit variable pharmacokinetics among patients. Our study represents the first comparison of a 5-day condensed regimen with a sequential 9-day regimen, both of which utilize intravenous targeted dosing of busulfan rather than oral busulfan. Given recent successful experience in refractory leukemias and older patients with conditioning regimens that administer busulfan over a longer period of time, a 9-day regimen of FluBu4 could potentially be a treatment consideration [11, 12] . However, contrary to what has been observed with such timed sequential regimens, our retrospective analysis suggests that a prolonged administration schedule of FluBu4 may lead to greater toxicity, requiring adjustments to methotrexate dosing which in turn resulted in higher GVHD rates. Therefore, although survival outcomes are similar between the two regimens, these findings indicate FluBu4 over 5 days is preferable over 9 days. Our data suggest that prospective comparisons of outcomes between sequential and concurrent regimens are required prior to widespread adoption of sequential conditioning regimens.
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